Study details
Enrolling now
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD
Massachusetts General Hospital
NCT IDNCT07079761ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
96
Study length
about 1.7 years
Ages
18–55
Locations
1 site in MA
About this study
Researchers are testing whether a single intravenous dose of allopregnanolone (Allo) compared to placebo promotes consolidation of extinction learning or blocks reconsolidation of physiological responses triggered by aversive memories. The trial also tests if Allo affects retention of non-aversive memories.
Based on ClinicalTrials.gov records.
What participants do
- 1.Participate in Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm
- 2.Participate in Experiment 1: Three-day aversive conditioning, extinction, and extinction retention testing paradigm
- 3.Participate in Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm
- +2 more
PhasePhase 2
Drug6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
infusion
Body systems
Psychiatry / Mental Health